Skip to main content

Table 3 Relationship between expression of total TNC, TNC-AD1 and TNC-AD2 and clinicopathological features of tumours

From: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women

Clinicopathological feature   Total TNC TNC-AD1 TNC-AD2
  n Mean Ct (95% CI) P Mean Ct (95% CI) P Mean Ct (95% CI) P
Age        
   ≤40 years 47 23.5 (21.8 to 25.3) 0.006 36.6 (35.4 to 37.7) <0.001 37.7 (36.7 to 38.6) 0.001
   >40 years 87 26.5 (25.7 to 27.3)   38.7 (38.1 to 39.3)   39.1 (38.5 to 39.7)  
Tumour type        
   IDC 109 25.4 (24.4 to 26.4) 0.554 37.8 (37.2 to 38.4) 0.079 38.7 (38.2 to 39.2) 0.760
   ILC 25 25.6 (24.7 to 26.5)   38.6 (37.1 to 40.0)   38.3 (36.5 to 39.9)  
Grade        
   I 14 27.6 (25.9 to 29.4) 0.109 39.1 (37.9 to 40.3) 0.017 39.8 (39.3 to 40.2) 0.066
   II 63 25.7 (24.6 to 26.7)   38.3 (37.4 to 39.1)   38.7 (37.9 to 39.5)  
   III 57 24.7 (23.2 to 26.1)   37.3 (36.4 to 38.2)   38.2 (37.4 to 39.0)  
Lymph node        
   Positive 63 25.4 (24.2 to 26.6) 0.802 37.9 (37.2 to 38.8) 0.978 38.8 (38.2 to 39.4) 0.900
   Negative 68 25.5 (24.4 to 26.7)   37.9 (37.1 to 38.8)   38.5 (37.7 to 39.3)  
   Not known 3       
Oestrogen receptor        
   Positive 89 25.6 (24.6 to 26.5) 0.413 38.2 (37.6 to 38.9) 0.011 38.7 (38.1 to 39.3) 0.316
   Negative 31 24.1 (22.2 to 26.1)   36.7 (35.3 to 38.0)   38.1 (36.9 to 39.3)  
   Not known 14       
Progesterone receptor       
   Positive 79 25.4 (24.5 to 26.4) 0.431 37.9 (37.2 to 38.4) 0.441 38.8 (38.2 to 39.3) 0.641
   Negative 36 24.5 (22.6 to 26.4)   37.6 (36.4 to 38.7)   38.1 (36.8 to 39.5)  
   Not known 19       
Her-2        
   Positive 17 23.3 (20.5 to 26.2) 0.232 37.6 (35.9 to 39.3) 0.639 38.2 (36.6 to 39.8) 0.452
   Negative 81 25.1 (24.2 to 26.1)   37.8 (37.0 to 38.6)   38.7 (38.0 to 39.4)  
   Not known 36       
Basal 1        
   Positive 23 24.3 (22.2 to 26.4) 0.605 36.9 (35.3 to 38.6) 0.170 38.4 (37.2 to 39.7) 0.746
   Negative 109 25.4 (24.5 to 26.3)   38.0 (37.4 to 38.7)   38.6 (37.9 to 39.1)  
   Not known 2       
Basal 2        
   Positive 22 25.8 (23.1 to 28.4) 0.103 37.6 (35.9 to 39.4) 0.960 38.5 (37.3 to 39.6) 1.000
   Negative 51 23.2 (21.4 to 25.0)   37.6 (36.6 to 38.7)   38.5 (37.7 to 39.3)  
   Not known 61       
  1. CI, confidence interval; Ct, number of cycles necessary to produce a product above background; IDC: infiltrating ductal carcinoma; ILC: infiltrating lobular carcinoma; TNC, tenascin-C.